ONVO vs. IKT, BCDA, GENE, SRNE, CHRO, COEP, MBOT, CELZ, TTNP, and PALI
Should you be buying Organovo stock or one of its competitors? The main competitors of Organovo include Inhibikase Therapeutics (IKT), BioCardia (BCDA), Genetic Technologies (GENE), Sorrento Therapeutics (SRNE), Chromocell Therapeutics (CHRO), Coeptis Therapeutics (COEP), Microbot Medical (MBOT), Creative Medical Technology (CELZ), Titan Pharmaceuticals (TTNP), and Palisade Bio (PALI). These companies are all part of the "medical" sector.
Organovo (NASDAQ:ONVO) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, community ranking, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.
Organovo received 191 more outperform votes than Inhibikase Therapeutics when rated by MarketBeat users. However, 83.33% of users gave Inhibikase Therapeutics an outperform vote while only 50.39% of users gave Organovo an outperform vote.
8.2% of Organovo shares are held by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are held by institutional investors. 4.0% of Organovo shares are held by insiders. Comparatively, 20.3% of Inhibikase Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Organovo has a net margin of 0.00% compared to Inhibikase Therapeutics' net margin of -5,886.15%. Inhibikase Therapeutics' return on equity of -147.03% beat Organovo's return on equity.
Inhibikase Therapeutics has a consensus price target of $27.00, suggesting a potential upside of 1,460.69%. Given Inhibikase Therapeutics' higher probable upside, analysts clearly believe Inhibikase Therapeutics is more favorable than Organovo.
Organovo has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500.
In the previous week, Inhibikase Therapeutics had 4 more articles in the media than Organovo. MarketBeat recorded 5 mentions for Inhibikase Therapeutics and 1 mentions for Organovo. Inhibikase Therapeutics' average media sentiment score of 0.50 beat Organovo's score of 0.00 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media.
Organovo has higher revenue and earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Organovo, indicating that it is currently the more affordable of the two stocks.
Summary
Inhibikase Therapeutics beats Organovo on 10 of the 17 factors compared between the two stocks.
Get Organovo News Delivered to You Automatically
Sign up to receive the latest news and ratings for ONVO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ONVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Organovo Competitors List
Related Companies and Tools
